In:
Blood Advances, American Society of Hematology, Vol. 2, No. 7 ( 2018-04-10), p. 777-786
Abstract:
Allo-HSCT using reduced intensity conditioning with alemtuzumab appears to be effective and safe for patients with refractory JIA. Early allo-HSCT may prevent joint damage, reduce toxicity associated with immunosuppression, and reduce transplant-related mortality.
Type of Medium:
Online Resource
ISSN:
2473-9529
,
2473-9537
DOI:
10.1182/bloodadvances.2017014449
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2018
detail.hit.zdb_id:
2876449-3
Bookmarklink